Beyond Canonical Immune Checkpoints: Overexpression of TNFRSF Members 4-1BB and OX-40 Marks T Cells Exhibiting Phenotypic Features of Exhaustion in Cervical Carcinoma
- PMID: 40387515
- DOI: 10.1111/imm.13945
Beyond Canonical Immune Checkpoints: Overexpression of TNFRSF Members 4-1BB and OX-40 Marks T Cells Exhibiting Phenotypic Features of Exhaustion in Cervical Carcinoma
Abstract
T cells are pivotal in combating cancer; however, they can become exhausted during tumour progression, losing their cytotoxic capacity and upregulating inhibitory receptors including PD-1 and TIGIT. While checkpoint blockade has emerged as a potent treatment option for numerous cancers, patient selection, long-term efficacy, and adverse effects still remain an issue. For these reasons, it is important to investigate other pathways that might lead to selective reactivation of the immune system. Co-stimulatory TNFRSF receptors, including 4-1BB and OX-40, have emerged as promising targets for reactivating exhausted T cells. However, their expression on exhausted peripheral and tumour-infiltrating lymphocytes (TILs) is not well characterised, particularly in cervical cancer (CC), which remains the leading cause of gynaecological cancer mortality in low- and middle-income countries. To investigate the expression of these receptors, PBMCs were collected from CC patients and healthy donors, along with TILs from tumour biopsies, and analysed using multiparametric flow cytometry. Our findings revealed an increased population of phenotypically exhausted (PD-1+TIGIT+) CD4+ and CD8+ T cells in TILs, and, to a lesser extent, in peripheral blood and from CC patients. These exhausted T cell subsets exhibited selective overexpression of 4-1BB and OX-40 compared to phenotypically non-exhausted cells (PD-1-TIGIT-). In TILs, 4-1BB was overexpressed 12.7-fold in CD8 cells with the exhausted phenotype, OX-40 was overexpressed 3.3-fold; in CD4 cells with the exhausted phenotype, the overexpression was 7.8× and 3.8× for 4-1BB and OX-40, respectively. CD8 and CD4 T cells that were PD-1 + TIGIT+ 4-1BB+ were 7.3× and 16× more likely to be found in the tumour versus peripheral blood. Additionally, subpopulations of PD-1high T cells were significantly elevated in the tumour-infiltrating T cells and TIGIT expression was positively associated with PD-1 levels in peripheral patient CD8+ and CD4+ T cells, potentially indicating an advanced state of exhaustion. These findings suggest that TNFRSF members, especially 4-1BB, may serve as potential immunotherapeutic targets for reinvigorating exhausted T cells in CC.
Keywords: 4‐1BB; CD4+ T cell; CD8+ T cell; OX‐40; PD‐1; TIGIT; cervical cancer.
© 2025 John Wiley & Sons Ltd.
Similar articles
-
Uncovering the Expression Pattern of the Costimulatory Receptors ICOS, 4-1BB, and OX-40 in Exhausted Peripheral and Tumor-Infiltrating Natural Killer Cells from Patients with Cervical Cancer.Int J Mol Sci. 2024 Aug 12;25(16):8775. doi: 10.3390/ijms25168775. Int J Mol Sci. 2024. PMID: 39201462 Free PMC article.
-
Unique immune characteristics and differential anti-PD-1-mediated reinvigoration potential of CD8+ TILs based on BRCA1/2 mutation status in epithelial ovarian cancers.J Immunother Cancer. 2024 Jul 4;12(7):e009058. doi: 10.1136/jitc-2024-009058. J Immunother Cancer. 2024. PMID: 38964784 Free PMC article.
-
Single-Cell Analyses Reveal a Functionally Heterogeneous Exhausted CD8+ T-cell Subpopulation That Is Correlated with Response to Checkpoint Therapy in Melanoma.Cancer Res. 2025 Apr 15;85(8):1424-1440. doi: 10.1158/0008-5472.CAN-23-3918. Cancer Res. 2025. PMID: 40042995
-
Interventions targeted at women to encourage the uptake of cervical screening.Cochrane Database Syst Rev. 2021 Sep 6;9(9):CD002834. doi: 10.1002/14651858.CD002834.pub3. Cochrane Database Syst Rev. 2021. PMID: 34694000 Free PMC article.
-
Home treatment for mental health problems: a systematic review.Health Technol Assess. 2001;5(15):1-139. doi: 10.3310/hta5150. Health Technol Assess. 2001. PMID: 11532236
References
-
- Instituto Nacional de Estadística y Geografía (INEGI), “Estadísticas a propósito del Día Internacional de la Lucha contra el Cáncer; INEGI,” 2024, https://www.inegi.org.mx/contenidos/saladeprensa/aproposito/2024/EAP_CAN....
-
- J. F. Grau‐Bejar, C. Garcia‐Duran, D. Garcia‐Illescas, O. Mirallas, and A. Oaknin, “Advances in Immunotherapy for Cervical Cancer,” Therapeutic Advances in Medical Oncology 15 (2023): 17588359231163836, https://doi.org/10.1177/17588359231163836.
-
- U.S. Food and Drug Administration, “FDA approves pembrolizumab with chemoradiotherapy for FIGO 2014 Stage III‐IVA cervical cancer,” https://www.fda.gov/drugs/resources‐information‐approved‐drugs/fda‐appro....
-
- M. Kagabu and T. Baba, “Enhanced Immune Checkpoint Inhibitor Therapy for Advanced Recurrent Cervical Cancer: The Key to Treatment Efficacy and Maintenance of Quality of Life,” eBioMedicine 108 (2024): 105386, https://doi.org/10.1016/j.ebiom.2024.105386.
-
- J. Niu, C. Maurice‐Dror, D. H. Lee, et al., “First‐in‐Human Phase 1 Study of the Anti‐TIGIT Antibody Vibostolimab as Monotherapy or With Pembrolizumab for Advanced Solid Tumors, Including Non‐Small‐Cell Lung Cancer☆,” Annals of Oncology 33, no. 2 (2022): 169–180, https://doi.org/10.1016/j.annonc.2021.11.002.
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Research Materials